Obiltoxaximab - Biologic Drug Details

Summary for obiltoxaximab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for obiltoxaximab

Recent Clinical Trials for obiltoxaximab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Elusys Therapeutics	Phase 1

See all obiltoxaximab clinical trials

Pharmacology for obiltoxaximab

Mechanism of Action	Anthrax Protective Antigen-directed Antibody Interactions
Established Pharmacologic Class	Anthrax Protective Antigen-directed Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for obiltoxaximab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for obiltoxaximab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Elusys Therapeutics, Inc.	ANTHIM	obiltoxaximab	Injection	125509		2036-04-06	DrugPatentWatch analysis and company disclosures
Elusys Therapeutics, Inc.	ANTHIM	obiltoxaximab	Injection	125509		2035-08-13	DrugPatentWatch analysis and company disclosures
Elusys Therapeutics, Inc.	ANTHIM	obiltoxaximab	Injection	125509		2035-08-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for obiltoxaximab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Elusys Therapeutics, Inc.	ANTHIM	obiltoxaximab	Injection	125509		2036-02-23	Patent claims search

International Patents for obiltoxaximab

Country	Patent Number	Estimated Expiration
Cyprus	1117331
European Patent Office	1951757
European Patent Office	2759550

Supplementary Protection Certificates for obiltoxaximab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C20220005 00356	Estonia		PRODUCT NAME: TAFASITAMAB;REG NO/DATE: EU/1/21/1570 01.09.2021
SPC/GB22/008	United Kingdom		PRODUCT NAME: TAFASITAMAB; REGISTERED: UK EU/1/21/1570(FOR NI) 20210901; UK FURTHER MA ON IPSUM 20210901
CR 2022 00007	Denmark		PRODUCT NAME: TAFASITAMAB; REG. NO/DATE: EU/1/21/1570 20210901

Obiltoxaximab: Market Dynamics and Financial Trajectory

Last updated: February 17, 2026

What is Obiltoxaximab?

Obiltoxaximab is a monoclonal antibody developed for the treatment and prevention of anthrax infection. It is designed to neutralize the lethal toxin produced by Bacillus anthracis. The drug targets the protective antigen (PA) component of the anthrax toxin, preventing it from binding to host cell receptors and initiating cellular damage [1].

Regulatory Status and Approvals

Obiltoxaximab received U.S. Food and Drug Administration (FDA) approval via the Animal Rule pathway in July 2016 [1]. This regulatory mechanism allows for drug approval based on efficacy data from animal studies when human trials are not ethical or feasible. In the case of anthrax, the inability to ethically challenge humans with the live pathogen necessitates reliance on animal models for efficacy demonstration.

The initial approval was granted to Anthrax Toxin Neutralizer (ATN) by Emergent BioSolutions (formerly BioThrax) [2]. Emergent BioSolutions currently holds the marketing exclusivity and manufacturing rights for obiltoxaximab.

Development and Manufacturing

Obiltoxaximab was developed by PharmAtⅳ, which was subsequently acquired by Emergent BioSolutions. The manufacturing process for biologic drugs like obiltoxaximab is complex and requires specialized facilities and stringent quality control measures. Emergent BioSolutions operates manufacturing sites capable of producing such biologics.

Market Landscape and Competition

The market for anthrax countermeasures is largely driven by governmental stockpiling programs, primarily in the United States. The Biomedical Advanced Research and Development Authority (BARDA) is a key customer, procuring medical countermeasures for the Strategic National Stockpile (SNS).

Current Competitive Landscape

The primary competitive product for obiltoxaximab in the U.S. is Raxibacumab, also developed by Emergent BioSolutions. Raxibacumab was approved in 2012 for the treatment of inhalational anthrax in conjunction with standard antibacterial therapy [3]. While both target anthrax toxin, they have different mechanisms of neutralization.

Other potential or historical anthrax therapeutics exist, but obiltoxaximab and raxibacumab are the most prominent FDA-approved biologic countermeasures. Antibacterial agents are the primary treatment for the bacterial infection itself; however, toxin-neutralizing antibodies are critical for addressing the systemic toxicity of the disease.

Future Market Dynamics

The demand for obiltoxaximab is intrinsically linked to U.S. government procurement cycles and national biodefense strategies. Changes in government funding for biodefense, shifts in threat assessments, or the development of new or improved countermeasures could impact future demand.

The acquisition of PharmAtⅳ by Emergent BioSolutions consolidated the development and commercialization of two leading anthrax antitoxin biologics under a single entity, simplifying the competitive landscape from the manufacturer's perspective but potentially reducing product diversity for the procurer.

Financial Trajectory and Revenue

Assessing the precise financial trajectory and revenue for obiltoxaximab is challenging due to its nature as a government-procured product and its integration into Emergent BioSolutions' broader portfolio. Revenue is primarily derived from contracts with BARDA.

Historical Contract Data

Emergent BioSolutions has secured multi-year contracts with BARDA for the procurement of anthrax vaccines and antitoxins. These contracts often involve development, manufacturing, and delivery of the product.

• BARDA Contract Extensions: In recent years, Emergent BioSolutions has received contract modifications and extensions from BARDA related to the procurement of its anthrax medical countermeasures, including products like obiltoxaximab [4]. These contracts are often valued in the hundreds of millions of dollars over their term.
• Reporting Specificity: Financial reports from Emergent BioSolutions typically aggregate revenue from its diverse product portfolio. Specific revenue attributed solely to obiltoxaximab is not usually itemized separately. However, its contribution is understood to be part of the company's broader government contract business segment.

Estimated Market Size and Value

The market for anthrax countermeasures is niche, driven by biodefense preparedness rather than direct patient care in a commercial setting. The value is in the stockpiling of sufficient quantities to address a potential biothreat.

• Government Stockpiling: The U.S. government maintains substantial stockpiles of medical countermeasures. The value of these stockpiles is influenced by factors such as the number of doses required, the unit cost of the drug, and the duration of shelf life.
• Contract Values: Typical BARDA contracts for similar biodefense products have ranged from tens to hundreds of millions of dollars over several years, covering manufacturing and delivery obligations. For example, contracts related to the broader anthrax countermeasure program have been substantial.

Factors Influencing Financial Performance

1. Government Procurement Cycles: The consistent and predictable procurement by BARDA is the primary driver of revenue. Any disruption to these cycles would directly impact financial performance.
2. Contract Renewal and Competition: The renewal of existing contracts and the absence of significant new competitive threats from other manufacturers are critical for sustained revenue.
3. Manufacturing Costs and Efficiency: The cost of goods sold for biologics can be high. Efficient manufacturing processes and supply chain management are essential for profitability.
4. Product Shelf Life and Replenishment: Biologics have expiration dates. Replenishment orders are necessary as products age out of their shelf life, creating ongoing demand.

Key Takeaways

Obiltoxaximab is an FDA-approved biologic antitoxin for anthrax, developed and marketed by Emergent BioSolutions. Its market is almost exclusively government-driven, with BARDA being the primary customer for U.S. strategic stockpiling. The financial trajectory is dictated by multi-year government contracts, with revenue primarily generated from these procurement agreements rather than commercial sales. Competition is limited, with raxibacumab, also from Emergent BioSolutions, being its primary counterpart. Future market dynamics are contingent on ongoing government funding for biodefense and the sustained need for anthrax countermeasures in national stockpiles.

Frequently Asked Questions

1. What is the primary indication for obiltoxaximab? Obiltoxaximab is indicated for the prophylaxis and treatment of inhalational anthrax in conjunction with antibacterial drugs.

2. Who manufactures obiltoxaximab? Obiltoxaximab is manufactured by Emergent BioSolutions.

3. How is obiltoxaximab approved for use? It received FDA approval under the Animal Rule pathway, based on efficacy data from animal studies due to the inability to conduct ethical human trials for anthrax exposure.

4. What is the main driver of obiltoxaximab's market demand? The primary driver is U.S. government stockpiling programs, specifically through procurement contracts with the Biomedical Advanced Research and Development Authority (BARDA).

5. What is the competitive landscape for obiltoxaximab? The main competitor is raxibacumab, another anthrax antitoxin also manufactured by Emergent BioSolutions. The market is largely consolidated with few direct biologic competitors.

---

Citations

[1] U.S. Food & Drug Administration. (2016, July 13). FDA approves first anthrax antitoxin for children and adults. [Press release]. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-anthrax-antitoxin-children-and-adults

[2] Emergent BioSolutions. (2016, July 13). Emergent BioSolutions Announces FDA Approval of Obiltoxaximab for Anthrax. [Press release]. Retrieved from https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-announces-fda-approval-obiltoxaximab-anthrax

[3] U.S. Food & Drug Administration. (2012, March 27). FDA approves new drug for treating inhalational anthrax. [Press release]. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treating-inhalational-anthrax

[4] Biomedical Advanced Research and Development Authority (BARDA). (Ongoing). BARDA Funding Opportunities and Contracts. (Information gathered from publicly available contract databases and BARDA announcements, specific contract numbers and dates may vary and are subject to governmental reporting).